Successful Demonstration of Prolonged Release of CBD in Dogs Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that in its recent study of its CBD-loaded liposome technology (LPT) on dogs, CBD showed prolonged plasma concentrations for at least six weeks after a single administration. These results are significant advance in the development of the technology demonstrating the advantages of LPT in dogs, which are good predictors to the behavior of LPT in humans.
The dog received a single administration of 5 mg/kg dose injected subcutaneously. CBD plasma profile of the dog is found in Fig 1. Importantly, the common practice of CBD oral doses is in the range of 1-4 mg/kg daily (given in two doses)1 with half-life of 4-5 h 2. This is translated to administration of 30-120 mg/kg per month as compared to the 5 mg/kg single LPT dose that was lasted for at least 6 weeks.
This study highlighted one of the advantages of the LPT technology over the oral CBD available formulations. These results open the door to a wide range of exciting therapeutic possibilities.
https://www.newsfilecorp.com/release/104195
